Observing Metabolism of EPA With Consideration of Genetics And Sex
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-35
SponsorUniversity of Toronto
About this trial
The goal of this clinical study is to learn how fast EPA is converted to other molecules, including DHA, with consideration of biological sex and genetics in healthy humans.
The main questions it aims to answer are:
* How fast is EPA converted to DHA in blood, and is the conversion rate affected by sex and a specific genotype we previously identified? * How do sex and the specific genotypes affect blood DHA levels and other products of DHA in response to dietary EPA? * How fast does dietary EPA replace blood EPA and other omega-3 fatty acids, and is the rate affected by sex and genotype?
Participants will be asked to take EPA supplements for 12 weeks and provide a series of venous blood samples over the study duration.
Eligibility criteria
Qualifiers
BMI between 18.5- 30 kg/m2
healthy
Disqualifiers
Consumption of fish/seafood or EPA/DHA-enriched foods currently or within the previous 6 months
Consumption of any supplements containing ALA/EPA/DHA currently or within the previous 6 months
Allergies to any component of the study supplement (fish, gelatin etc.)
BMI <18.5 kg/m² or >30 kg/m²
Trial design
Treatments tested in this trial
- EPA 2.4g/day
Treatment groups
64 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov